Overview
- A 14-member FDA Pharmacy Compounding Advisory Committee voted narrowly on July 23–24 to recommend adding six of seven unapproved peptides to the 503A bulks list so U.S. compounding pharmacies could make them for prescription use.
- Career FDA scientists and staff had urged against loosening restrictions, saying the peptides lack robust human clinical trials, have unclear chemical definitions, and carry safety risks such as immune reactions or cancer‑promotion potential.
- Reporting shows several new advisory members had ties to peptide clinics or vendors and Health and Human Services Secretary Robert F. Kennedy Jr. has publicly supported broader peptide access, raising questions about conflicts of interest.
- Investigations and independent tests have found gray‑market peptide samples with impurities, inconsistent doses and even toxic contaminants, a reality supporters say compounding could curb and critics say reclassification may not stop.
- The panel’s vote is only advisory; the FDA and HHS will review staff analyses, conflict disclosures and public comments before any rulemaking, a process that could take months to a year or longer and will shape patient access and safety oversight.